Fenofibrate and Pharmacogenetic Impact in Dyslipidemia

Completed

Conditions studied: Dyslipidemia

In brief

The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body handles the drug) and drug targets (how the drug acts on the body) influences how a person responds to the lipid lowering medication-fenofibrate.

Key facts

Study ID

NCT00613613

Run by

University of Minnesota

People needed

56

Starts

2008-01-01

Expected to finish

2013-12-01

Last updated by the study team

2020-01-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18-75 year old
• Be willing to participate in the study and attend the scheduled clinic exams
• Consent to taking lipid lowering therapy for 4 weeks and if necessary discontinue lipid lowering agents for a period of 8 weeks

You may not qualify if…

• <18 years of age
• History of liver, kidney, pancreas, pancreatitis, gall bladder disease or malabsorption (Crohn's disease etc.)
• Use of insulin or currently taking warfarin
• Pregnant women or women of childbearing potential not using an acceptable form of contraception
• History of an allergy or hypersensitivity to fenofibrate
• Investigational drug use within 30 days of the study
• A disease that, in the opinion, of the PI, would put the subject at risk during the study

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.